{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:04:17Z","timestamp":1793289857117,"version":"4.5.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heterozygous familial hypercholesterolaemia (HeFH) is a genetic disorder, characterized by high plasma concentrations of low-density lipoprotein cholesterol (LDL-C) from birth. This study aimed to assess the efficacy and safety of recaticimab, a new humanized anti-PCSK9 antibody capable of reducing LDL-C levels in patients with poorly controlled HeFH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>REMAIN-3 was a multicentre, randomized, double-blind, placebo-controlled Phase 3 study done at 25 sites in China. Patients with a genetic or clinical diagnosis of HeFH, who were on stable lipid-lowering therapy for \u226528 days, had fasting LDL-C \u2265 2.6\u2005mmol\/L (or \u22651.8\u2005mmol\/L for those with a history of atherosclerotic cardiovascular disease), and had fasting triglyceride \u22645.6\u2005mmol\/L, were randomly allocated in a 2:1 ratio to receive subcutaneous recaticimab at 150\u2005mg or matching placebo every 4 weeks for 12 weeks. The primary endpoint was the percentage change in LDL-C from baseline to Week 12. Overall, 143 patients underwent randomization and received recaticimab (n = 95) or placebo (n = 48). At Week 12, the mean percentage change in LDL-C from baseline was \u221254.4% (95% CI, \u221257.9 to \u221250.8%) in the recaticimab group and \u22124.5% (95% CI, \u22129.4 to 0.3%) in the placebo group, with a treatment difference of \u221249.8% (95% CI, \u221255.8 to \u221243.9%; P &amp;lt; 0.0001). Recaticimab was superior to placebo in improving other lipid variables, including non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein a. Treatment-related adverse events (TRAEs) were comparable between groups (27.4% with recaticimab vs. 25.0% with placebo). The most common TRAEs occurring more frequently with recaticimab than placebo were injection site reaction (8.4% vs. 0%) and increased blood creatine phosphokinase (5.3% vs. 2.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Recaticimab significantly lowered the LDL-C level compared with placebo, with an acceptable safety profile, providing a new effective treatment option for patients with inadequately controlled HeFH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT04844125<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cvr\/cvaf155","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:57:54Z","timestamp":1757073474000},"page":"1856-1864","source":"Crossref","is-referenced-by-count":9,"title":["Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study"],"prefix":"10.1093","volume":"121","author":[{"given":"Liwen","family":"Li","sequence":"first","affiliation":[{"name":"Cardiovascular Medicine, Guangdong Provincial People's Hospital , No. 106, Zhongshan 2nd Road, Guangzhou 510080 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanjuan","family":"Deng","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd. , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlong","family":"Sheng","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, The Second Hospital of Anhui Medical University , Hefei ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, The Second Xiangya Hospital of Central South University , Changsha ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Ling","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, The Second Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luya","family":"Wang","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Chuiyangliu Hospital Affiliated to Tsinghua University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuilian","family":"Dai","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Xiamen Cardiovascular Hospital Xiamen University , Xiamen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufang","family":"Lian","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Yan'an University Xianyang Hospital , Xianyang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixin","family":"Yu","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, The Xiangya Hospital of Central South University , Changsha ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Yang","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University , Zhengzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Hu","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, The First People's Hospital of Kashgar , Kashgar ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuGang","family":"Dong","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, The First Affiliated Hospital, Sun Yat-sen University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Gansu Provincial People's Hospital , Lanzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, The First Hospital of Hebei Medical University , Shijiazhuang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, The First Affiliated Hospital of Nanjing Medical University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Han","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Shanxi Cardiovascular Hospital , Taiyuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuhua","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Union Medical Center , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Shenzhen People's Hospital , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzi","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Medical University Second Hospital , Tianjin ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3404-8582","authenticated-orcid":false,"given":"Biao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Gulou Hospital Affiliated to Nanjing University School of Medicine , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd. , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd. , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Guangdong Provincial People's Hospital , No. 106, Zhongshan 2nd Road, Guangzhou 510080 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"2025102409265015400_cvaf155-B1","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025102409265015400_cvaf155-B2","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1161\/CIRCULATIONAHA.115.020701","article-title":"Heterozygous familial hypercholesterolemia","volume":"133","author":"Onorato","year":"2016","journal-title":"Circulation"},{"key":"2025102409265015400_cvaf155-B3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2025102409265015400_cvaf155-B4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Authors\/Task Force Members","year":"2019","journal-title":"Atherosclerosis"},{"key":"2025102409265015400_cvaf155-B5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","article-title":"Overview of the current status of familial hypercholesterolaemia care in over 60 countries\u2014the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"277","author":"Vallejo-Vaz","year":"2018","journal-title":"Atherosclerosis"},{"key":"2025102409265015400_cvaf155-B6","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2025102409265015400_cvaf155-B7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2025102409265015400_cvaf155-B8","first-page":"237","article-title":"Chinese guidelines for lipid management (2023)","volume":"38","author":"Joint Committee on the Chinese Guidelines for Lipid Management","year":"2023","journal-title":"Chin Circ J"},{"key":"2025102409265015400_cvaf155-B9","first-page":"99","article-title":"Chinese expert consensus: Screening, diagnosis and treatment of familial hypercholesterolemia","volume":"46","author":"Atherosclerosis and Coronary Heart Disease Group of the Chinese Society of Cardiology of Chinese Medical Association","year":"2018","journal-title":"Chin J Cardiol"},{"key":"2025102409265015400_cvaf155-B10","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2025102409265015400_cvaf155-B11","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3390\/cells11192972","article-title":"PCSK9 inhibition: from current advances to evolving future","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"2025102409265015400_cvaf155-B12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12916-021-02208-w","article-title":"PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b\/2 study","volume":"20","author":"Xu","year":"2022","journal-title":"BMC Med"},{"key":"2025102409265015400_cvaf155-B13","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.jacc.2024.07.035","article-title":"Recaticimab monotherapy for nonfamilial hypercholesterolemia and mixed hyperlipemia: the phase 3 REMAIN-1 randomized trial","volume":"84","author":"Xu","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025102409265015400_cvaf155-B14","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2024.09.012","article-title":"Recaticimab as add-on therapy to statins for nonfamilial hypercholesterolemia: the randomized, phase 3 REMAIN-2 trial","volume":"84","author":"Sun","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025102409265015400_cvaf155-B15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"2025102409265015400_cvaf155-B16","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"2025102409265015400_cvaf155-B17","doi-asserted-by":"crossref","first-page":"100774","DOI":"10.1016\/j.lanepe.2023.100774","article-title":"Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study","volume":"36","author":"Hansen","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2025102409265015400_cvaf155-B18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab","volume":"146","author":"Hagstr\u00f6m","year":"2022","journal-title":"Circulation"},{"key":"2025102409265015400_cvaf155-B19","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2025102409265015400_cvaf155-B20","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2025102409265015400_cvaf155-B21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"2025102409265015400_cvaf155-B22","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"key":"2025102409265015400_cvaf155-B23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1042\/CS20180040","article-title":"PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate","volume":"132","author":"Croyal","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"2025102409265015400_cvaf155-B24","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","article-title":"Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor","volume":"32","author":"Sun","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025102409265015400_cvaf155-B25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/joim.13457","article-title":"PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration","volume":"291","author":"Ying","year":"2022","journal-title":"J Intern Med"},{"key":"2025102409265015400_cvaf155-B26","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvaf155\/64215658\/cvaf155.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/121\/12\/1856\/64215658\/cvaf155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/121\/12\/1856\/64215658\/cvaf155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T13:27:06Z","timestamp":1761312426000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/121\/12\/1856\/8248561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,5]]},"published-print":{"date-parts":[[2025,10,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvaf155","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,5]]}}}